RTNS 2012

Better tools needed to assess clinical trials

The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.

By Emily Singer
14 May 2012 | 6 min read

Trials and tribulations

Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.

By Emily Singer
11 May 2012 | 3 min read

Compensatory mechanisms

Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.

By Emily Singer
8 May 2012 | 3 min read

Debate over quality of adult-derived stem cells rages on

As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably. 

By Emily Singer
7 May 2012 | 8 min read

Complex case

Multiple levels of complexity make it challenging to develop drugs to treat autism.

By Emily Singer
4 May 2012 | 3 min read

Fast-forward

In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.

By Emily Singer
27 April 2012 | 3 min read

Explore more from The Transmitter

Brain organoid size matches intensity of social problems in autistic people

Overgrown organoids could point to mechanisms underlying profound autism.

By Holly Barker
18 July 2024 | 5 min read

Persistent protein pairing enables memories to last

The complex of two memory proteins, rather than the individual molecules acting independently, underlie month-long memories in mice, a new study suggests.

By Elissa Welle
17 July 2024 | 5 min read
A digitally distorted image of a file folder against a blue gradient background.

Data access changes to UK Biobank stir unease in neuroscientists

“I feel a little bit in limbo,” says neuroscientist Stephanie Noble, who has paused a study using Biobank data after the repository shifted from a data download to a cloud-only access model.

By Calli McMurray
16 July 2024 | 7 min read